Related Experiment Videos
Osteopontin and colon cancer progression
Timothy J Yeatman1, Ann F Chambers
1H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA. Yeatman@moffitt.usf.edu
Clinical & Experimental Metastasis
|March 26, 2003
Summary
Researchers identified osteopontin as a promising new marker for colon cancer progression. This discovery aims to improve early detection and patient management for this deadly disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colon cancer causes significant mortality in the US, with metastasis being the primary driver of death.
- Despite advances, survival rates for colon cancer have remained stagnant for decades.
- Understanding colon cancer progression and metastasis is crucial for improving patient outcomes.
Purpose of the Study:
- To develop a molecular encyclopedia of new tumor markers and progression markers for colon cancer.
- To identify clinically useful markers for detecting and predicting colon cancer stage and disease burden.
- To apply gene expression profiling to discover novel biomarkers.
Main Methods:
- Utilized gene expression profiling technology.
- Screened approximately 12,000 named genes.
- Focused on identifying markers associated with tumor progression and metastasis.
Main Results:
- Identified osteopontin as a leading candidate clinical marker.
- The study aimed to discover markers with potential for clinical management of colon cancer patients.
- Osteopontin shows potential for detecting and predicting disease stage and burden.
Conclusions:
- Osteopontin is a promising novel biomarker for colon cancer.
- Gene expression profiling is a valuable tool for discovering colon cancer markers.
- Further research into osteopontin could lead to improved clinical management strategies.